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Introduction: Zinc oxide nanoparticles (ZnO NPs) have recently attracted attention as 
potential anti-cancer agents. To the best of our knowledge, the toxicity of ZnO NPs against 
human chronic myeloid leukemia cells (K562 cell line) has not been studied using transcrip-
tomics approach.
Objective: The goals of this study were to evaluate the capability of ZnO NPs to induce 
apoptosis in human chronic myeloid leukemia cells (K562 cells) and to investigate the 
putative mechanisms of action.
Methods: We used viability assay and flowcytometry coupled with Annexin V-FITC and 
propidium iodide to investigate the toxicity of ZnO NPs on K562 cells and normal peripheral 
blood mononuclear cells. Next we utilized a DNA microarray-based transcriptomics 
approach to characterize the ZnO NPs-induced changes in the transcriptome of K562 cells.
Results: ZnO NPs exerted a selective toxicity (mainly by apoptosis) on the leukemic cells 
(p≤0.005) and altered their transcriptome; 429 differentially expressed genes (DEGs) with 
fold change (FC)≥4 and p≤0.008 with corrected p≤0.05 were identified in K562 cells post 
treatment with ZnO NPs. The over-expressed genes were implicated in “response to zinc”, 
“response to toxic substance” and “negative regulation of growth” (corrected p≤0.05). In 
contrast, the repressed genes positively regulated “cell proliferation”, “cell migration”, “cell 
adhesion”, “receptor signaling pathway via JAK-STAT” and “phosphatidylinositol 3-kinase 
signaling” (corrected p≤0.05). Lowering the FC to ≥1.5 with p≤0.05 and corrected p≤0.1 
showed that ZnO NPs over-expressed the anti-oxidant defense system, drove K562 cells to 
undergo mitochondrial-dependent apoptosis, and targeted NF-κB pathway.
Conclusion: Taken together, our findings support the earlier studies that reported anti- 
cancer activity of ZnO NPs and revealed possible molecular mechanisms employed by 
ZnO NPs to induce apoptosis in K562 cells.
Keywords: transcriptomics, ZnO NPs, CML, apoptosis
Introduction
There has been growing interest in nanoparticles (NPs) as promising therapeutic 
agents due to their distinctive physiochemical characteristics and surface reactivity.1 
We and others have reported selective toxicity of metal NPs, such as gold NPs and 
sliver NPs, against various types of malignant cells including acute promyelocytic 
leukemia cells (HL-60),2 cervical carcinoma cells (HeLa),3 hepatocellular carci-
noma cells (HepG2),4,5 lung cancer cell (A549),5,6 and breast cancer cells (MDA- 
MB-231).7 Another interesting class of metal NPs is in the oxide form, such as zinc 
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oxide NPs (ZnO NPs), which have been extensively stu-
died in the context of cancer therapy.8 Numerous reports 
have shown the potential of ZnO NPs to preferentially 
target the survival of malignant cells with no or little effect 
on normal cells. For example, our previous work has 
reported the induction of programmed cell death in acute 
promyelocytic leukemia cells (HL60) upon treatment with 
ZnO NPs, with minimal effects on normal peripheral 
blood mononuclear cells (PBMCs).9 Similar findings 
were reported by others in breast cancer cells (MCF7),10 
colon cancer cells (Caco-2),11 hepatocellular carcinoma 
cells (HepG2),12 lung adenocarcinoma (A549),12 ovarian 
cancer cells (SKOV3)13 and cervical carcinoma cells 
(HeLa).14 The mechanism through which ZnO NPs kill 
cancer cells has not been fully characterized, but it appears 
to be linked to the increased concentration of Zn ions 
inside treated cells that results in zinc-dependent protein 
activity disequilibrium.15 As Zn is a co-factor for many 
human enzymes, alteration of its intracellular concentra-
tion affects a variety of biological processes, such as DNA 
replication, DNA damage repair, apoptosis and oxidative 
stress.16 Furthermore, ZnO NPs elevate the production of 
reactive oxygen species (ROS) through the pro-inflamma-
tory response of the treated cells towards the NPs and via 
their surface reactivity that functions as a redox reaction 
system.8 Increased ROS production leads to oxidative 
stress-induced DNA damage, which can drive pro-
grammed cell death.17
Unlike the methods of conventional molecular biology 
that enable the assessment of gene expression at a small scale 
(for a single or few genes), DNA-microarray-based transcrip-
tomics is a well-established approach that allows global gene 
expression profiling of all human coding-genes in a single 
assay.18 Therefore, transcriptomics is an attractive tool to 
better understand the underlying mechanisms of cytotoxicity 
of NPs against cancer cells. Following the same concept, 
different researchers utilized transcriptomic approach to 
identify ZnO NPs-induced transcriptomics alterations in 
malignant cells, such as lung cancer cells (A549),19 colon 
carcinoma cells (RKO),20 colorectal adenocarcinoma cells 
(Caco-2),20 melanoma cells (SK Mel-28),20 acute monocytic 
leukemia cells (THP-1)21 and acute T-cell leukemia cells 
(Jurkat A3).22 Based on “PubMed” search using the key 
words “ZnO nanoparticles gene expression” or “ZnO nano-
particles transcriptomics”, and to the best of our knowledge, 
the toxicity of ZnO NPs on human chronic myeloid leukemia 
(CML) cells (K562) has not been studied using transcrip-
tomic technologies. K562 is a hematopoietic multipotential 
malignant blast that spontaneously differentiates into mye-
loid progenitors.23
CML is a hematological neoplasm that affects the mye-
loid linage and represents 15% of all adult leukemias.24 
According to the Surveillance, Epidemiology, and End 
Result program (SEER), it is estimated that nearly 9000 
patients will be diagnosed with CML in the United Stated 
in 2019, and 1140 patients will die of the neoplasm in the 
same year. A key factor of the tumorigenesis of CML is 
fusion of ABL on chromosome 9 with BCR on chromosome 
22 as a result of the chromosomal translocation t(9;22).25 The 
BCR-ABL fused gene has a persistent tyrosine kinase activ-
ity that supports the survival and growth of the tumor.25 
Despite the improvements in the clinical outcomes following 
the introduction of tyrosine kinase inhibitors (TKIs), such as 
imatinib and dasatinib, in the therapy of CML, the disease 
remains fatal for at least 20% of patients.26,27 Therefore, 
there is still need for alternative treatment, especially for 
those who show poor response to TKIs.
Given the promise of ZnO NPs as potential cancer 
therapy, we investigated the cytotoxicity and the transcrip-
tomic-related mechanisms of action of ZnO NPs on human 
CML cell line (K562).
Materials and Methods
Cell Culture
Human K562 cells (cell line of chronic myeloid leukemia) 
were obtained from the American Type Culture Collection 
(ATCC). The leukemic cells were grown in RPMI 1640 
medium supplemented with 10% fetal calf serum (FCS), 
100 U/mL penicillin, 40 μg/mL gentamycin, 100 μg/mL 
streptomycin sulphate, 4.5 mg/mL glucose and 2 mg/mL 
sodium bicarbonate under an atmosphere of humidified air 
containing 5% CO2 at 37 °C. Peripheral blood mononuc-
lear cells were isolated by density-gradient centrifugation 
using Lymphoprep from blood of healthy donors. PBMCs 
were stimulated in RPMI 1640 medium supplemented 
with 10% FCS, 5 μg/mL phytohemagglutinin, 100 U/mL 
penicillin, 40 μg/mL gentamycin, 100 μg/mL streptomycin 
sulphate, 4.5 mg/mL glucose and 2 mg/mL sodium bicar-
bonate for 3 days at 37 °C under an atmosphere of humi-
dified air containing 5% CO2. Next the PBMCs were 
transferred to a medium as the above but which lacked 
phytohemagglutinin and contained 5 ng/mL of interleukin 
2 and were incubated at 37 °C in a CO2 incubator for 
subsequent analysis.
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Cell Viability
To determine the toxicity of the ZnO NPs (Sigma-Aldrich 
#721077) against K562 cells, suspensions of K562 cells 
(3×105 cells/mL) in RPMI 1640 medium supplemented with 
10% FCS were seeded into a 96-well culture plate (200 μL/ 
well) in the presence of increasing concentrations of ZnO NPs 
(0 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL, 40 μg/mL, 50 μg/ 
mL, 60 μg/mL, 70 μg/mL and 80 μg/mL). The K562 cells 
were then incubated for 5 days at 37 °C with the presence of 
CO2. The incubation of the cells was continued with no change 
of the culture medium.
To assess the toxicity of the ZnO NPs on normal PBMCs 
compared with K562 cells, four concentrations of the NPs 
(0 μg/mL, 20 μg/mL, 40 μg/mL, and 80 μg/mL) were selected. 
Suspensions of PBMCs (3×105 cells/mL) in culture medium 
(RPMI 1640 with 10% FCS and 5 ng/mL interleukin 2) and 
suspensions of K562 cells (3×105 cells/mL) in culture medium 
(RPMI 1640 supplemented with 10% FCS) were indepen-
dently seeded into a 96-well culture plate (200 μL/well) 
containing different concentrations of the NPs (0 μg/mL, 
20 μg/mL, 40 μg/mL, and 80 μg/mL). Next, the cells were 
continuously incubated for 5 days at 37 °C with the presence 
of CO2 with no change of the culture medium.
To investigate whether ZnO NPs induce time-dependent 
toxicity against K562 cells, suspensions of K562 cells (3×105 
cells/mL) in RPMI 1640 medium with 10% FCS were seeded 
in a 96-well plate containing 10 μg/mL ZnO NPs. The cells 
were incubated for 5 different periods of time (24 hours, 48 
hours, 72 hours, 96 hours and 120 hours) at 37 °C with the 
presence of CO2 with no change of the culture medium.
At the end of each period of incubation time mentioned 
above, MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide] assay was employed to determine the 
viability K562 cells and PBMCs. The culture medium was 
replaced carefully with fresh RPMI 1640 supplemented 
with 10% FCS with diluted MTT dye (final concentration 
0.5 mg/mL) and then incubated at 37 °C for 3 hours. After 
removing the previous incubated medium, the formazan 
crystals were dissolved in DMSO (200 μL). The reduced 
levels of MTT were quantified using the absorbance 
microplate reader, which measured the light absorbance, 
using a wavelength of 570 nm.28 All experiments were 
performed in triplicate.
Dissolution Analysis
To determine the concentration of zinc ions released from 
ZnO NPs to liquid medium, suspensions of ZnO NPs 
(0 μg/mL, 10 μg/mL, 20 μg/mL, 40 μg/mL and 80 
μg/mL) in complete culture medium (RPMI 1640) were 
incubated at 37 °C for two periods of time (15 hours and 
24 hours). Next, centrifugation at 20,000 rpm for 30 min-
utes was employed to sediment the non-dissolved ZnO 
NPs. The supernatant was transferred to new tubes, and 
the centrifugation step was repeated. Next, the supernatant 
was transferred to new tubes, and zinc concentration was 
measured using an inductive coupled plasma mass spectro-
metry (Thermo Fisher Scientific).
Identification of the Type of Cell Death
To identify the kind of cell death induced by ZnO NPs in K562 
cells, suspensions of the leukemic cells (3×105 cells/mL) in 
RPMI 1640 supplemented with 10% FCS were seeded into 
a 6-well plate in the absence of ZnO NPs (control cells) and in 
the presence of 40 μg/mL of ZnO NPs. The plate was then 
incubated for 3 days at 37 °C with the presence of CO2. The 
incubation of the cells was contiguous with no change of the 
culture medium. FACS analysis of cellular death was carried 
out using an Annexin V-FITC Kit (Trevigen, Inc.) at two time 
points of the incubation time (15 hours and 72 hours). In brief, 
cells (3×105 cells/mL) were washed with cold 1X phosphate 
buffered saline (1X PBS) and centrifuged for 5 minutes at 
300×g. Next, washed cells were resuspended in a staining 
solution containing fluorescein-labeled Annexin V, propidium 
iodide and 1X binding buffer. The cells in the staining solution 
were incubated for 15 minutes in the dark at room temperature. 
Next, 1X binding buffer was added to the stained cells that 
were transferred into a FACS tube for subsequent analyses. 
The stained cells were then analyzed using FACS CantoII flow 
cytometer coupled with FACSdiva software (Becton 
Dickinson). The experiments were performed in triplicate.
RNA Extraction and Quality Control
Total RNA was isolated from K562 cells using the materi-
als and the instructions provided in RNeasy Mini Kits 
(QIAGEN). The purity and quantity of the extracted 
RNA was quantified using NanoDrop ND-1000 spectro-
photometer (Thermo Fisher Scientific, Inc.). Only RNA 
samples with high purity (260 nm/280 nm ≥2) were used. 
The integrity of the isolated RNA was determined using 
the RNA Nano 6000 chips and the Agilent 2100 
Bioanalyzer according the manufacturer’s instructions 
(Agilent Technologies, Inc.). Only RNA samples with 
good integrity (RNA Integrity Number (RIN) ≥8) were 
used.
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The transcriptome of K562 cells was studied by following 
the instructions in the Agilent protocol of “one-color 
microarray-based gene expression analysis”. Briefly, 100 
ng of the extracted RNA from K562 cells and the RNA 
spikes from RNA Spike-In Kit, One-Color (Agilent) were 
converted to cDNA that was transcribed and amplified to 
fluorescent-labeled cRNA using the low input quick amp 
labeling (one-color) kit (Agilent). Next the labeled cRNA 
was purified using the materials and protocol of RNeasy 
Mini Kits (QIAGEN). Then, NanoDrop ND-1000 spectro-
photometer (Thermo Fisher Scientific, Inc.) was used to 
determine the quality and quantity of the labeled cRNA; 
only samples with 260 nm/280 nm ≥2, cRNA yield ≥825 
ng and specific activity (pmol Cy3/μg cRNA) ≥6 were 
moved on to the next steps. Hybridization samples were 
prepared by mixing 600 ng of the labeled cRNA with 5 μL 
of 10× Gene Expression Blocking Agent (Agilent) and 
1 μL of 25× Fragmentation Buffer (Agilent); sample total 
volume was 25 μL. Next the hybridization samples were 
incubated for 30 min at 60°C to fragment the labeled 
cRNA. Hybridization samples were then cooled, and 25 
μL of 2× Hi-RPM hybridization Buffer (Agilent) was 
added in order to stop the cRNA fragmentation (sample 
total volume = 50 μL). From each hybridization sample 40 
μL was dispensed onto a gasket that was assembled to 
SurePrint G3 Human Gene Expression 8×60K Microarray 
slide (Agilent) and incubated at 65°C for 17 hours. Next, 
the microarray slides were washed with the Gene 
Expression Washing Buffer 1 and 2 to which 0.005% 
Triton X-102 was added (Agilent) and scanned using 
Agilent SureScan Microarray Scanner with the 
AgilentG3_GX_1color protocol. Next, quantitative data 
of probe features from the scanned microarray slide were 
extracted using Agilent Feature Extraction Software (ver-
sion 11.0.1.1; Agilent Technologies, Inc.) and saved for 
subsequent data analyses.
Data Analysis and Filter Criteria
The data that were extracted using Agilent Feature 
Extraction Software (version 11.0.1.1; Agilent 
Technologies, Inc.) were loaded into the GeneSpring GX 
version 12.1 software package (Agilent Technologies, 
Inc.). To obtain the normalized signal value of the probes, 
the extracted data were log2 transformed and normalized 
on the basis of percentile shift algorithm with percentile 
target equal to 75. Only measurements from probes with 
either flag of “detected” or “not detected” were used in the 
present study. Two conditions were created; treated condi-
tion that included the ZnO NPs-treated samples (n= 3), and 
untreated condition that accommodated the untreated sam-
ples (control samples; n= 3). Probes were filtered on the 
basis of flag calls, where in our analyses only probes with 
flag “detected” in all samples in one of the two conditions 
were considered for further analyses. Differentially 
expressed genes (DEGs) in the treated samples versus 
the untreated samples were identified according to the 
fold change (FC). To focus on the most apparent DEGs 
in the two groups of samples, we set the FC to 4-fold or 
above with p≤0.008 and corrected p≤0.05. Next, we 
decreased the FC cut-off to ≥1.5-fold with p≤0.05 and 
corrected p≤0.1 in order to widen the search for DEGs 
that may have roles in the mode of action of ZnO NPs. 
Cluster analyses and heatmap presentations of DEGs were 
conducted using hierarchical algorithm and were based on 
probes (normalized signal value of probes) and conditions 
with Euclidean method for similarity measure and Wards 
for linkage rule. Gene ontology (GO) enrichment analyses 
were conducted using the GeneSpring GX version 12.1 
software package (Agilent Technologies, Inc.) and only 
over-represented GO terms with corrected p≤0.05 were 
reported. GO enrichment analyses of the DEGs were also 
performed using the gProfiler (https://biit.cs.ut.ee/gprofi 
ler/gost);29 the option “only annotated genes” was selected 
for statistical domain scope and corrected p-value cut-off 
was set at ≤0.05. We used the Ingenuity Pathway Analysis 
(IPA) Core analysis suite (Qiagen Biosciences) for under-
standing the functional significance and relevance of 
DEGs. For selecting the most significant canonical path-
ways, we utilized a cut-off -log(p-value)>3. Top upstream 
regulators and network were also derived from IPA 
analysis.
Statistical Analysis
Paired Student’s t-test was used to calculate the p values; 
and Benjamini–Hochberg false discovery rate (FDR) was 
employed to determine the corrected p values. The 
p values and corrected p values of DEGs were calculated 
using the GeneSpring GX version 12.1 software package 
(Agilent Technologies, Inc.). Excel software was used to 
calculate the p values of the viability assay and the ana-
lyses titled identification of the type of cell death. Excel 
software was also utilized to calculate the means and 
standard deviations; and to construct the column graphs.
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Results
Cellular Viability and Identification of the 
Type of Cell Death
The preparation and characterization of the ZnO NPs used 
in the present study were previously reported by 
Triboulet et al.30 To assess the impact of ZnO NPs on 
the viability of K562 cells, we conducted MTT assay on 
K562 cells that were treated with increasing concentra-
tions of ZnO NPs (from 0 μg/mL to 80 μg/mL) for five 
days (120 hours). The MTT assay showed cytotoxicity of 
ZnO NPs on the leukemic cells with the mean CC50 being 
20 μg/mL (Figure 1A).
Next, the impact of the ZnO NPs on the viability of 
normal PBMCs as opposed to K562 cells was investigated. 
The cells were incubated with four concentrations of the 
ZnO NPs (0 μg/mL, 20 μg/mL, 40 μg/mL, and 80 μg/mL) 
for five days (120 hours). Figure 1B shows that the ZnO 
NPs had little effect on the survival of the PBMCs; ZnO 
NPs at concentration of 40 μg/mL reduced the viability of 
the PBMCs to 91.3% compared with 21% in the K562 
cells. Even at high concentration of ZnO NPs (80 μg/mL) 
the viability of the PBMCs dropped only to 88.4% com-
pared with 1% for the K562 cells. These findings indicated 
a selective toxicity of the ZnO NPs towards leukemic 
cells.
We also conducted an experiment to determine whether 
the ZnO NPs induce time-dependent toxicity on K562 
cells. K562 cells were incubated with 10 μg/mL of ZnO 
NPs for five periods of time (24 hours, 48 hours, 72 hours, 
96 hours and 120 hours). MTT assay showed that there 
was greater loss of the cell viability as the incubation time 
increased (Figure 1C).
Next, we conducted dissolution analysis of the ZnO NPs. 
The analysis was performed on suspensions of ZnO NPs in 
culture medium RPMI 1640 (0 μg/mL, 10 μg/mL, 20 μg/mL, 
40 μg/mL and 80 μg/mL) that were incubated for 15 hours or 
24 hours at 37 °C. Figure 1D shows that the release of zinc 
ions from the ZnO NPs to the culture medium appeared to be 
dose-dependent and time-dependent. For example, the con-
centration of zinc ions found in the supernatant of the culture 
medium was 1.04 μg/mL (incubation time = 15 hours) and 
1.6 μg/mL (incubation time = 24 hours) for the ZnO NPs at 
10 μg/mL. For the ZnO NPs at 80 μg/mL the released zinc 
ions were found to be 5.9 μg/mL (incubation time = 15 hours) 
and 8.4 μg/mL (incubation time = 24 hours).
We employed Annexin V-FITC and PI to identify the 
type of cellular death induced by ZnO NPs on K562 cells. 
The investigation was performed using flowcytometry on 
K562 cells that were treated with 40 μg/mL of ZnO NPs 
for 15 hours or 72 hours and on untreated K562 cells (with 
the same incubation time). Our findings indicated that ZnO 
NPs induced apoptosis in K562 cells at the two periods of 
incubation time (15 hours and 72 hours). In comparison 
with the untreated cells (control samples), the treated cells 
(15 hours) showed an increase in apoptotic population 
(doubly positive cells for annexin V-FITC and PI; 
p=0.0006; n=3 versus 3; Figure 1E and F); and the viabi-
lity of the treated cells dropped to 73% compared with 
98% for the control cells (p=0.0005; n=3 versus 3). For the 
longer exposure of the cells (72 hours) to ZnO NPs, the 
treated cells showed an increase in the early and late 
apoptotic populations (p≤0.005; n=3 versus 3; Figure 1E 
and F). Interestingly, the viability loss of the K562 cells 
caused by ZnO NPs was mainly driven by apoptosis rather 
than necrosis even with the long exposure (72 hours) to the 
NPs, in which the viability of the treated cells drastically 
decreased to 5.2% as opposed to 84% of the control cells 
(p≤0.0008; n=3 versus 3). The treated K562 cells with 40 
μg/mL of ZnO NPs for 15 hours (n = 3) and the untreated 
K562 cells (n = 3) were stored for subsequent analyses.
Altered Transcriptomics Signature Was 
Associated with ZnO NPs-Treated K562 
Cells
In an attempt to characterize the ZnO NPs-induced tran-
scriptomics changes that drive K562 cells to undergo 
apoptosis, we compared the transcriptome of the two 
groups of K562 cells; the group that was treated with 40 
μg/mL of ZnO NPs for 15 hours (where the cellular 
viability decreased to 73% mainly by apoptosis) and the 
untreated group that had cellular viability of 98% (n=3 
versus 3; Figure 1E and F). The comparison was restricted 
to probes that were detected in all samples in one of the 
two groups (number of IDs=30,902). Initially, we set the 
following criteria: FC≥4 with p≤0.008 and corrected 
p≤0.05, to define genes with differential expression in 
the treated samples versus untreated samples. By applying 
these criteria to our transcriptomics data sets, we found 
508 probes (429 genes) with altered expression in K562 
cells as a result of treatment with ZnO NPs 
(Supplementary Table 1). Of these genes, 159 were over- 
expressed and 270 were down-expressed in the treated 
cells. Figure 2 shows a volcano plot of the gene expression 
profiling of the 30,902 probes and a hierarchical cluster 
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Figure 1 Cytotoxicity assessment of ZnO NPs on leukemic and normal cells; and dissolution analysis of the NPs in culture medium. MTT assay was used to measure the 
viability of K562 cells (A) and PBMCs (B) post treatment with different concentrations of ZnO NPs for 120 hours. MTT assay was also used to determine the viability of 
K562 cells post incubation with 10 μg/mL for five different periods of time (C). Dissolution analysis was conducted to determine the concentration of released Zn ions from 
ZnO NPs to the culture medium RPMI 1640 (D). Annexin V-FITC and propidium iodide (PI) with flow cytometer were used to identify the kind of death caused by ZnO NPs 
(40 μg/mL) in K562 cells (E). The data of flow cytometer were presented using column graph (F). All experiments were conducted in triplicate. PBMCs: peripheral blood 
mononuclear cells. Asterisk symbol was used to define p values; p ≤ 0.01 is ** and p ≤ 0.001 is ***.
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analysis with heatmap of the DEGs (FC≥4; p≤0.008; cor-
rected p≤0.05).
To gain insights into the biological roles of these DEGs we 
conducted gene ontology (GO) enrichment analyses as 
described in the methods. Table 1 shows the significantly 
over-represented biological processes by the DEGs (corrected 
p≤0.05). The over-expressed genes showed significant enrich-
ments of similar pathways that are related to the cellular 
response to toxic chemical. For example, eight different 
types of metallothionein-1 (MT1) over-represented the 
Figure 2 A transcriptomic signature was associated with ZnO NPs-treated K562 cells. Volcano plot shows differentially expressed genes (DEGs: FC≥4; p≤0.008; corrected 
p≤0.05) in the ZnO NPs-treated K562 cells versus untreated K562 cells (A). Hierarchical cluster analysis with heatmap presentation was performed on the DEGs (B). The 
color range represents the normalized signal value of probes (log2 transformation and 75 percentile shift normalization).
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biological process “cellular response to zinc ions” (corrected 
p=1.06×10−11; Figure 3A). Furthermore, the same eight genes 
enriched the term “negative regulation of growth” (corrected 
p=0.007). Another group of genes (n= 41), including 
metallothioneins (MT1), hemoglobin subunits (HBB, HBA2 
and HBZ), lipid metabolism genes (ACSL6 and ACSS1), zinc 
exporter (SLC30A1), oxidative responsive genes (SOD3 and 
DUSP1), heat shock genes (HSPA1A and HSPH1) and 
Table 1 Pathway Enrichment Analysis of the Differentially Expressed Genes (DEGs: FC≥4; p≤0.008; Corrected p≤0.05) in the ZnO 
NPs-Treated K562 Compared with the Untreated K562 Cells
GO Accession 
No







GO:0097501 Stress response to metal ion Up 5.23E-17 10 16 GP
GO:0061687 Detoxification of inorganic compound Up 5.23E-17 10 16 GP
GO:0006882 Cellular zinc ion homeostasis Up 4.44E-15 11 35 GP
GO:0071294 Cellular response to zinc ion Up 1.06E-11 8 12 GS
GO:0009636 Response to toxic substance Up 2.55E-11 21 88 GP
GO:0071276 Cellular response to cadmium ion Up 7.14E-07 6 14 GS
GO:0071241 Cellular response to inorganic substance Up 2.26E-06 10 105 GS
GO:0010035 Response to inorganic substance Up 6.80E-06 15 360 GS
GO:0010038 Response to metal ion Up 6.80E-06 13 250 GS
GO:0045926 Negative regulation of growth Up 0.007 9 210 GS
GO:0009636 Response to toxic substance Up 0.01 11 356 GS
GO:0042221 Response to chemical Up 0.01 41 3716 GS
GO:0001816 Cytokine production Down 8.15E-08 31 811 GP
GO:0002376 Immune system process Down 0.000012 54 2004 GS
GO:0002684 Positive regulation of immune system process Down 0.00002 29 723 GS
GO:0002274 Myeloid leukocyte activation Down 0.00005 11 94 GS
GO:0001775 Cell activation Down 0.00006 26 624 GS
GO:0032944 Regulation of mononuclear cell proliferation Down 0.0001 13 170 GS
GO:0046427 Positive regulation of receptor signaling pathway via 
JAK-STAT
Down 0.007 6 91 GP
GO:0002275 Myeloid cell activation involved in immune response Down 0.0002 7 36 GS
GO:1903037 Regulation of leukocyte cell-cell adhesion Down 0.0005 14 227 GS
GO:0032946 Positive regulation of mononuclear cell proliferation Down 0.0009 10 114 GS
GO:0007166 Cell surface receptor signaling pathway Down 0.001 46 1948 GS
GO:0097529 Myeloid leukocyte migration Down 0.001 8 73 GS
GO:0042531 Positive regulation of tyrosine phosphorylation of 
STAT protein
Down 0.002 6 72 GP
GO:000716 Signal transduction Down 0.003 81 4557 GS
GO:0022409 Positive regulation of cell-cell adhesion Down 0.004 12 212 GS
GO:0014068 Positive regulation of phosphatidylinositol 3-kinase 
signaling
Down 0.007 6 90 GP
GO:0006935 Chemotaxis Down 0.01 20 617 GS
GO:1903708 Positive regulation of hemopoiesis Down 0.03 7 187 GP
GO:0045861 Negative regulation of proteolysis Down 0.04 10 361 GP
GO:0008593 Regulation of Notch signaling pathway Down 0.04 5 107 GP
GO:0002696 Positive regulation of leukocyte activation Down 0.04 11 248 GS
GO:0098657 Import into cell Down 0.05 16 483 GS
GO:0043410 Positive regulation of MAPK cascade Down 0.05 13 552 GP
GO:0045766 Positive regulation of angiogenesis Down 0.05 7 206 GP
GO:0030335 Positive regulation of cell migration Down 0.05 12 297 GS
GO:0002757 Immune response-activating signal transduction Down 0.05 12 297 GS
Note: The source of the findings shown in this table is (GS) GeneSpring GX version 12.1 software package (Agilent Technologies, Inc.) and (GP) gProfiler. 
Abbreviations: GO, gene ontology; Reg, expression regulation of the genes that enriched GO terms; Corr p, corrected p value that was calculated on the basis of 
Benjamini–Hochberg false discovery rate (FDR). Count in selection, number of genes that were assigned to a GO term; Count in total, number of all genes that have been 
known to function in a GO term.
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myeloid cytoskeleton gene (SPTB), over-represented the bio-
logical process “response to chemicals” (corrected p=0.01; 
Figure 3B). Of note, in addition to the SLC30A1 and 
SLC7A8 that with other genes enriched the term “response to 
chemicals”, another four solute carriers (SLC17A4, SLC22A4, 
SLC39A8 and SLCO4A1; Supplementary Table 1) were also 
Figure 3 Over-expressed genes in the ZnO NPs-treated K562 cells compared with the untreated K562 cells. Hierarchical cluster analysis with heatmap presentation was 
conducted on the over-expressed genes (FC≥4; p≤0.008; corrected p≤0.05) that significantly over-represented the biological processes “cellular response to zinc ions and 
negative regulation of growth” (A) and “response to chemicals” (B). The color range represents the normalized signal value of probes (log2 transformation and 75 percentile 
shift normalization).
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over-expressed in the treated cells. Similarly, the increased 
expression of myeloid cytoskeleton SPTB in the treated cells 
was combined with an over-expression of two other myeloid 
cytoskeleton genes (EPB41L4A and EPB42; Supplementary 
Table 1). Furthermore, the over-expression of the eight genes 
that were negative regulators of growth (metallothioneins) in 
the treated cells was associated with over-expression of three 
genes that antagonize cellular survival (GADD45B, EGR1 and 
HIP1R; Supplementary Table 1).
The GO analyses of the down-expressed genes (FC≥4; 
p≤0.008; corrected p≤0.05) in the treated cells demon-
strated a positive regulation of these genes on immune 
response, cell activation, cell proliferation, cell migration, 
cell adhesion and signal transduction (Table 1). For 
instance, 26 genes, such as stem cell growth factor recep-
tor (KIT), signal transducer (CD24), AP-1 family tran-
scription factor (BATF), protein tyrosine-protein 
phosphatase (PTPRC) and phosphoinositide-3-kinase 
(PIK3CG) over-represented the term “cell activation” (cor-
rected p=6.01×10−5; Figure 4A). In addition, 10 genes 
including insulin like growth factor 1 (IGF1) and hemato-
poietic protein 1 (NCKAP1L, also known as HEM1) 
enriched the biological process “positive regulation of 
mononuclear cell proliferation” (corrected p=0.0009; 
Figure 4B). The term “positive regulation of cell adhe-
sion” was over-represented by 12 genes (corrected 
p=0.004; Figure 4C) that were among the genes that 
enriched both “cell activation” and “positive regulation 
of mononuclear cell proliferation”. The chemokines 
(CCL5, CXCL1 and CXCL3) with the vascular endothelial 
growth factor A (VEGFA) and other eight genes over- 
represented the term “positive regulation of cell migra-
tion” (corrected p = 0.05; Figure 4D). Eight genes includ-
ing IGF1, KIT, IL18, PIK3CG enriched three pathways 
termed “positive regulation of tyrosine phosphorylation 
of STAT protein“ (corrected p=0.002), “positive regulation 
of receptor signaling pathway via JAK-STAT” (corrected 
p=0.007), “positive regulation of phosphatidylinositol 
3-kinase signaling” (corrected p=0.007) as shown in 
Figure 5. Our findings also indicated a decreased produc-
tion of cytokines in the treated cells as evidenced by the 
over-represented term “cytokine production” by 41 genes 
with down-expression in the treated cells (corrected 
p=8.15×10−8); and by the reduced expression of 17 genes 
that encode for cytokines or cytokine receptors (p≤0.007 
and corrected p≤0.05; Figure 6). The genes LGALS3, 
IGFL2, NLRP7, NUPR1, NCKAP1L and S1PR3 that are 
known to support cellular survival were found to be down- 
expressed in the treated cells (Supplementary table 1).
Ingenuity pathway analysis (IPA) showed that the DEGs 
(FC≥4; p≤0.008; corrected p≤0.05) significantly enriched 
pathways named: IL-10 signaling (-log(p-value) 
=7.66×10−7; overlap=9/69), SPINK1 cancer pathway (-log 
(p-value)=7.66×10−7;overlap = 9/69), FXR/RXR activation 
(-log(p-value)=2071×10−6; overlap=11/126) and dendritic 
cell maturation (-log(p-value)=3.47×10−6; overlap=13/ 
183). SPINK 1 cancer pathway was predicted to be inhib-
ited (z-score=−2.33), but dendritic cell maturation pathway 
was activated (z-score=3.464). Activity prediction for the 
other two pathways could not be determined. Among the 
top upstream regulators, TNF was most significant and 
predicted to be activated (z-score=4.432) and p-value of 
overlap was 2.71×10−15. TNF affected 76 genes among 
the DEGs. Other top regulators were TGFB1 
(p=1.20×10−13) and IFNG (p=1.62×10−12). All these regu-
lators were predicted to be activated. Top network among 
the DEGs was associated with molecular transport and 
inflammatory response. A network of 35 genes was con-
structed from the DEGs, of which 23 were part of this 
network. Presence of BCL2A1, SOCS1 and IL13 genes 
was conspicuous (Figure 7).
Oxidative Stress Responsive Genes
As mentioned earlier, one mode of action that ZnO NPs use to 
target the survival of cancer cells is by increasing the produc-
tion of ROS leading to oxidative stress-induced cell death.15,31 
Therefore, we examined our transcriptomics data sets to deter-
mine whether oxidative stress responsive genes showed 
altered expression as consequence of the treatment with ZnO 
NPs. Among the DEGs (FC≥4; p≤0.008; corrected p≤0.05), 
there were four genes that have been implicated in the 
response to oxidative stress; superoxide dismutase 3 (SOD3), 
dual specificity phosphatase 1 (DUSP1) and heat shock pro-
tein family A (Hsp70) member 1A (HSPA1A) exhibited over- 
expression in the treated cells, while apolipoprotein E (APOE) 
recorded down-expression. To expand our search for oxidative 
stress responsive genes with altered expression post treatment 
with ZnO NPs, we set the FC threshold to ≥1.5 with p≤0.05 
and corrected p≤0.1. Consequently, 35 genes were found with 
differential expression (Figure 8). Of these genes 24 were 
over-expressed and 11 were down-expressed in the treated 
cells. Of note, superoxide dismutases (SOD2 and SOD3), 
synuclein alpha (SNCA), 24-dehydrocholesterol reductase 
(DHCR24), oxidation resistance 1 (OXR1), apurinic/apyrimi-
dinic endodeoxyribonuclease 1 (APEX1; also known as 
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Figure 4 Down-expressed genes in the ZnO NPs-treated K562 cells compared with the untreated K562 cells. Hierarchical cluster analysis with heatmap presentation was 
applied on the down-expressed genes (FC≥4; p≤0.008; corrected p≤0.05) that significantly enriched the biological processes “cell activation” (A), “positive regulation of 
mononuclear cell proliferation” (B), “positive regulation of cell adhesion” (C) and “positive regulation of cell migration” (D). The color range represents the normalized 
signal value of probes (log2 transformation and 75 percentile shift normalization).
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oxidative repair protein) peroxiredoxin 4 (PRDX4), frataxin 
(FXN) and sulfiredoxin 1 (SRXN1) showed an over-expression 
in the treated cells. Interestingly, the other member of super-
oxide dismutase family (SOD1) also recorded higher expres-
sion in the treated cells (FC=1.46; p=0.01; corrected p=0.06). 
In contrast, aldo-keto reductase family 1 member C3 
(AKR1C3), glutathione peroxidase 1 (GPX1), pyrroline-5- 
carboxylate reductase 1 (PYCR1) and thioredoxin reductase 
2 (TXNRD2) showed down-expression in the treated cells.
Apoptotic Genes
Our flow cytometric analysis indicated that ZnO NPs 
induced apoptosis in K562 cells. In agreement with this 
finding, our DEGs (FC≥4; p≤0.008; corrected p≤0.05) 
Figure 5 ZnO NPs targeted pathways that promote cellular proliferation and survival. ZnO NPs reduced the expression of genes (FC≥4; p≤0.008; corrected p≤0.05) that 
significantly enriched “positive regulation of tyrosine phosphorylation of STAT protein” (IGF1, IL18, IL23A, KIT, CCL5 and HES1), “positive regulation of receptor signaling 
pathway via JAK-STAT” (IGF1, IL18, IL23A, KIT, CCL5 and HES1) and “positive regulation of phosphatidylinositol 3-kinase signaling” (IGF1, PIK3CG, IL18, KIT, CCL5 and UNC5B). 
The gene expression data were shown from three ZnO NPs-treated K562 samples and three untreated K562 samples. The normalized signal value of probes was generated 
by log2 transformation and 75 percentile shift normalization of the raw data.
Figure 6 Expression of cytokine and cytokine receptor genes in the ZnO NPs-treated K562 cells compared with the untreated K562 cells. The fold change (FC) of the gene 
expression was based on the data that were recorded in three ZnO NPs-treated K562 samples and three untreated K562 samples. All FC data had p≤0.007 and corrected 
p≤0.05.
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showed that genes with antagonistic effect on cellular 
survival (MT1A, MT1H, MT1X, MT1B, MT1M, MT1F, 
MT1E, MT1G, GADD45B, EGR1 and HIP1R) were over- 
expressed in the treated cells, whereas genes that augment 
cellular survival (VEGFA, KIT, IGF1, LGALS3, INPP5D, 
IGFL2, NLRP7, NUPR1, NCKAP1L and S1PR3) were 
down-expressed (Supplementary Table 1). However, our 
DEGs (FC≥4; p≤0.008; corrected p≤0.05) did not include 
other core apoptotic genes, such as those that belong to 
tumor necrosis receptor superfamily and their ligands, 
BCL2 family or caspases. Therefore, we widened the 
search for apoptotic genes by decreasing the FC threshold 
Figure 7 Network of differentially expressed genes (DEGs) is associated with molecular transport and inflammatory response. A network of 35 genes was constructed to 
understand the cross-talk between genes and functional relevance of this network. Red colored nodes indicated genes from the DEGs, whereas nodes with no color were 
not from the DEGs that was used for generating this network. Arrows show the direction of effect. The numbers under the genes are as follows from the top to bottom: p 
value, corrected p value, fold change (FC) of the DEGs, and log FC.
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(FC≥1.5 with p≤0.05 and corrected p≤ 0.1). Figure 9A 
and B show expression profiling of anti-apoptotic genes 
and pro-apoptotic genes, respectively. Seven anti-apoptotic 
genes, among which Fas apoptotic inhibitory molecule 2 
(FAIM2, also known as LFG), cell death regulator (AVEN), 
apoptosis inhibitor (API5) and apoptosis regulator 
(MCL1), were over-expressed in the treated cells. In con-
trast, nine anti-apoptotic genes, such as BCL2 related 
protein A1 (BCL2A1), baculoviral IAP repeat containing 
3 (BIRC3), TNF alpha induced protein 8 (TNFAIP8), p53 
inhibitor (MDM4) and CASP8 and FADD like apoptosis 
regulator (CFLAR), were down-expressed post treatment 
with ZnO NPs. Twelve pro-apoptotic genes like growth 
arrest and DNA damage inducible genes (GADD45B and 
GADD45G), cell death inducing DFFA like effectors 
(CIDEB and CIDEC), tumor protein p53 inducible protein 
3 (TP53I3), BCL2 associated transcription factor 
1 (BCLAF1, also known as BTF), SIVA1 apoptosis indu-
cing factor (SIVA1), BCL2 like 11 (BCL2L11, also known 
as BIM) and DNA fragmentation factor subunit beta 
(DFFB) were over-expressed in the treated cells. On the 
other hand, eight pro-apoptotic genes, such as death asso-
ciated protein kinase 1 (DAPK1), caspases (CASP8 and 
CASP10), death receptors including TNF receptor super-
family member 1A (TNFRSF1A), TNF receptor superfam-
ily member 10b (TNFRSF10B) and Fas cell surface death 
receptor (FAS), TNF superfamily members (TNFSF10 and 
TNFSF12) showed down-expression following treatment 
with ZnO NPs. Although BAX, which is a pro-apoptotic 
gene, did not meet the FC cut-off (FC≥1.5-fold), it showed 
an over-expression in the treated cells (FC=1.21, p=0.05).
NF-κB Pathway
The aforementioned changes in the transcriptome of K562 
cells post treatment with ZnO NPs revealed reduced 
expression of genes such as KIT, CXCL1, VEGFA, 
NUPR1, BCL2A1, TNFAIP8, BIRC3, and CFLAR (also 
known as FLICE-like IP), which were previously reported 
to promote the activation or expression of NF-κB pathway, 
or to be downstream targets of NF-κB pathway. These data 
suggested down-regulation of NF-κB pathway in K562 
cells by ZnO NPs. Therefore, we studied the expression 
of I-kappa-B-kinase beta (IKBKB) and the subunits of NF- 
κB. Although the FC was smaller than 4, Figure 10 shows 
that the treated cells exhibited reduced expression of 
IKBKB (FC=3.4, p=0.007; corrected p=0.05), NFKB2 
(also known as p100 subunit; FC=2.42; p=0.001; corrected 
p=0.03), RELB (FC=2; p=0.01; corrected p=0.06) and REL 
(also known as c-REL; FC=1.42; p=0.03; corrected 
p=0.09).
Discussion
ZnO NPs have been reported to cause cytotoxicity on 
a diverse range of cancer cells.15 Our current findings 
support this, as ZnO NPs were found to induce apoptosis 
in the CML cells line, K562. Our data indicated that the 
toxicity of ZnO NPs was limited to the leukemic cells but 
that normal PBMCs were not affected. Furthermore, we 
found that the toxicity of ZnO NPs on K562 cells was 
driven by apoptosis but not necrosis even when the leu-
kemic cells were over-exposed to the NPs (72 hours). 
Performing microarray transcriptomics analysis on treated 
cells with viability loss = 25% identified transcriptomics 
alterations that preceded ZnO NPs-induced apoptosis 
(because 75% of the treated cells had not yet undergone 
apoptosis). Therefore, these transcriptomics changes were 
likely to underpin the apoptotic impact of ZnO NPs on 
K562 cells. Interestingly, our molecular findings 
Figure 8 K562 cells altered the expression of their oxidative stress responsive 
genes in response to the treatment with ZnO NPs. Hierarchical cluster analysis 
with heatmap presentation demonstrated changes in the expression of oxidative 
stress responsive genes in the ZnO NPs-treated K562 cells as opposed to the 
untreated K562 cells. The altered gene expression was identified with fold change 
≥1.5, p≤0.05 and corrected p≤0.1. The color range represents the normalized signal 
value of probes (log2 transformation and 75 percentile shift normalization)
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(transcriptomics data) agreed with, and to a large extent 
explained, our cellular results that demonstrated an apop-
tosis induction in K562 cells by ZnO NPs. For example, 
the treatment with ZnO NPs increased the expression of 
genes that play roles in the “response to zinc ions”, 
“response to toxic substance”, “detoxification of inorganic 
compound”, “response to chemical” and “negative regula-
tion of growth”. Amongst these genes were eight types of 
MT1, which are known to be important for the intracellular 
homeostasis of zinc ions, detoxification of heavy metal 
ions and suppression of tumor growth.32 In line with this, 
four transcriptomics studies that were conducted on 
immune cells (HMDM, MDDC and Jurkat),22 embryonic 
kidney cells (HEK293),33 lung cancer cells (A549),19 and 
keratinocyte cells (HaCaT)34 that were exposed to ZnO 
NPs consistently reported an over-expression of genes 
implicated in Zn homeostasis including MT1 genes. 
Interestingly, decreased expression of MT1 genes was 
reported in a wide range of neoplasms of different organs 
Figure 9 ZnO NPs induced changes in the expression of apoptotic genes in K562 cells. Hierarchical cluster analysis and heatmap presentation showed altered expression of 
anti-apoptotic genes (A) and pro-apoptotic genes (B) in the ZnO NPs-treated K562 cells compared with the untreated K562 cells. All differentially expressed genes were 
found with fold change ≥1.5, p≤0.05 and corrected p≤0.1. The color range represents the normalized signal value of probes (log2 transformation and 75 percentile shift 
normalization).
Figure 10 ZnO NPs targeted NF-κB pathway in K562 cells. The treatment with 
ZnO NPs reduced the expression of NF-κB pathway activator IKBKB (FC=3.4, 
p=0.007; corrected p=0.05) and the NF-κB subunits: NFKB2 (FC=2.42; p=0.001; 
corrected p=0.03), RELB (FC=2; p=0.01; corrected p=0.06) and REL (FC=1.42; 
p=0.03; corrected p=0.09). The gene expression data were obtained from three 
samples of ZnO NPs-treated K562 cells and three samples of untreated K562 cells. 
The normalized signal value of probes was generated by log2 transformation and 75 
percentile shift normalization of the raw data.
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including breast, colon, stomach, lung and prostate.32 
Importantly, MT1 genes exert tumor suppressor activity 
in a number of malignancies, such as hepatocellular carci-
noma (MT1X, MT1M, MT1H and MT1G),35–38 prostate 
cancer (MT1H and MT1E)39,40 and thyroid cancer 
(MT1G, MT1M).41,42 Given the onco-suppression feature 
of MT1 genes, it is possible that their over-expression 
promoted apoptosis in the ZnO NPs-treated K562 cells. 
In consistence with this observation, FOS, which antago-
nizes proliferation and promotes apoptosis,43 was also 
found to be over-expressed in K562 cells post treatment 
with ZnO NPs. Furthermore, other genes that are known to 
target cellular survival such as GADD45B,44,45 EGR146,47 
and HIP1R48 were also identified with over-expression in 
the treated cells.
Given the roles of heat shock proteins in the protection 
of cells against stress induced by hypoxia, drugs or other 
chemical agents,49 the elevated expression of HSPA1A and 
HSPH1 is likely to be a defense mechanism of K562 cells 
against the cytotoxicity of ZnO NPs. Similarly, the treated 
cells also raised the expression of SLC30A1 that exports 
intracellular Zn ions out of cells to maintain Zn 
homeostasis.50 Other transcriptomics studies also reported 
an over-expression of SLC30A1 upon treatment with ZnO 
NPs.19,22 Furthermore, the cytoskeleton genes (SPTP, 
EPB41L4A and EPB42) of erythrocytes, for which K562 
cells are progenitor leukemic blasts, were found with over- 
expression in the treated cells possibly to overcome the 
ZnO NPs toxicity that were reported previously to alter the 
expression of structural proteins and cause cytoskeleton 
collapse.51,52
Our transcriptomics data showed that ZnO NPs 
reduced the expression of genes implicated in the positive 
regulation of “immune response”, “cell activation”, “cell 
proliferation”, “cell migration”, “cell adhesion” and “sig-
nal transduction”. For example, KIT, which is a key recep-
tor whose signaling is essential for the activation, survival 
and proliferation of hematopoietic stem cells,53,54 BATF, 
which plays significant roles in the survival and prolifera-
tion of blood cells,55,56 and PTPRC, which is required for 
hemopoiesis and homing of leukemic cells to bone 
marrow,57 were down-expressed following the treatment 
with ZnO NPs. Other interesting genes including IGF1, 
VEGFA and NCKAP1L, which promote the survival, pro-
liferation and migration of cancer cells,58–64 were also 
down-expressed in the treated cells. Our findings support 
the results of an earlier transcriptomics study that reported 
reduced expression of NCKAP1L and BATF in immune 
cells upon treatment with ZnO NPs.22 Our study also 
demonstrated decreased migration capacity of K562 cells 
post treatment with ZnO NPs as evidenced by the down- 
expression of migration genes, such as CCL5, CXCL1 and 
CXCL3.65 These chemokine genes not only play roles in 
the cellular migration, but are also important for the sur-
vival and proliferation of leukemic cells.66–68 The tyrosine 
phosphorylation of STAT and constitutive signaling of 
JAK-STAT were implicated in the tumorigenesis of differ-
ent types of leukemia.69,70 Therefore, blocking the JAK- 
STAT signal transduction or targeting STAT was shown to 
significantly inhibit the survival and proliferation of leu-
kemic cells.71,72 Similarly, PI3K signaling plays important 
roles in the extended survival and growth of various kinds 
of leukemia, and was reported by several studies to be a 
promising therapeutic target in blood cancer.73–75 
Interestingly, ZnO NPs were found in the present study 
to target the STAT phosphorylation, JAK-STAT pathway 
and PI3K signaling in K562 cells by reducing the expres-
sion of genes that positively regulate them. Therefore, our 
findings support the notion that NPs target STATs in can-
cer cells.76 Of note, genes that were previously reported to 
inhibit apoptosis, such as LGALS3,77 NLRP7,78 NUPR1,79 
and S1PR3,80 were identified in our transcriptomics data 
with down-expression post treatment with ZnO NPs. 
Taken together, the ZnO NPs-induced changes in the tran-
scriptome of K562 cells (molecular findings; DEGs: 
FC≥4; p≤0.008; corrected p≤0.05) were consistent with 
a cytotoxic phenotype of K562 cells caused by ZnO NPs 
(cellular findings). Furthermore, the transcriptomics profil-
ing identified molecular mechanisms through which ZnO 
NPs promoted apoptosis in K562 cells.
A growing body of evidence showed that ZnO NPs 
significantly increase the production of ROS promoting 
oxidative stress-induced cellular death.15,31,81 As a defense 
mechanism, cells increase the expression of oxidative 
stress responsive genes (anti-oxidant genes), such as 
SOD family, in order to neutralize the oxidative stress to 
escape cellular death.82 However, when the oxidative 
insult is persistent and overweighs the cellular anti-oxidant 
defense, the cells undergo apoptosis.83 Interestingly, in 
vitro and in vivo studies reported that ZnO NP-induced 
ROS production was associated with increased activity 
and expression of the anti-oxidant genes, SOD, catalase, 
PRDX2 and GSH.34,84,85 In line with this view, our current 
study showed altered expression of oxidative stress 
responsive genes in K562 cells post treatment with ZnO 
NPs. For example, genes like SOD2 (also known as 
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mitochondrial SOD), which protects cells from superoxide 
anion radicals by converting these to hydrogen peroxide 
and oxygen,86 SOD3 (extracellular SOD), which guards 
the extracellular region from ROS by intermediating the 
conversion of superoxide to hydrogen peroxide and 
oxygen,87 ORX-1, which positively regulates the expres-
sion of genes that detoxify hydrogen peroxide,88 PRDX4, 
which reduces hydrogen peroxide and organic hydroper-
oxides to water and alcohols,89 were over-expressed in 
K562 cells in response to ZnO NPs. In contrast, genes 
including GPX1, which converts peroxides to water and 
alcohol,90 and TXNRD2, which keeps thioredoxin in the 
reduced state,91 were down-expressed in the treated K562 
cells. Our findings indicated an altered expression of anti- 
oxidant genes in the ZnO NPs-treated cells, probably to 
antagonize the oxidative insult of the NPs.
In line with the apoptotic effect of the ZnO NPs on 
K562 cells, our transcriptomics data sets showed changes 
in the expression of apoptotic genes and proposed that 
ZnO NPs caused mitochondrial-dependent apoptosis in 
K562 cells, which was probably triggered by oxidative 
stress-induced DNA damage. For instance, among the 
over-expressed pro-apoptotic genes in the treated cells 
were BCLTF1, which is required for the transcription of 
TP53 in response to DNA damage, and P53I3, which is 
a downstream target of p53 that functions in the p53- 
dependent apoptosis pathway.92,93 In contrast, MDM4, 
which suppresses the activation of p53 in the event of 
DNA damage, was down-expressed in the treated cells. 
Interestingly, pro-apoptotic genes that are required for the 
DNA fragmentation during apoptosis, such as CIDEB, 
CIDEC, GADD45G, GADD45B and DFFB, were found 
to be over-expressed in the treated cells.44,94–96 The treated 
cells also exhibited increased expression of BIM, which is 
an initiator of the intrinsic apoptosis pathway,97 and 
SIVA1, which binds to and inhibits the anti-apoptotic 
gene BCL-XL allowing the mitochondrial-dependent apop-
tosis to occur.98 In line with these findings, the treated 
cells reduced the expression of BCL2A1, which antago-
nizes the release of cytochrome c from mitochondria by 
sequestering the pro-apoptotic effectors BAX and BAK.99 
Similarly, CFLAR, which suppresses the release of cyto-
chrome c from mitochondria,100 and BIRC3, which inhi-
bits the activation of CASP3 and CASP7,101 demonstrated 
decreased expression in the treated cells. In contrast, the 
treated cells increased the expression of anti-apoptotic 
genes, such as AVEN, which interferes with activation of 
caspases, and MCL1, which inhibits the release of 
cytochrome c from the mitochondria by interacting with 
BH3-only pro-apoptotic proteins.102,103 This finding could 
perhaps be explained, at least partially, by the over- 
expressed anti-oxidant defense in the treated cell. Anti- 
oxidant enzymes such as SOD were found to increase the 
expression of anti-apoptotic genes like AVEN and 
MCL1.104,105 Strikingly, there was reduced expression of 
genes that play key proapoptotic roles in the extrinsic 
apoptosis pathway, such as FAS,106 TNFRSF1A (also 
known as TNFR-1),107 TNFRSF10B (also known as 
TRAIL-R2) and its ligand TNFSF10 (also known as 
TRAIL),108 and CASP8.109 These data strongly support 
the idea that the intrinsic apoptosis pathway was respon-
sible for the ZnO NPs-induced death of K562 cells. 
Overall, our findings agree with the notion that ZnO NPs 
change the expression of apoptotic genes leading to mito-
chondrial-dependent apoptosis and revealed novel genes 
whose altered expression plays a potential role in this 
process.
NF-κB pathway has been heavily implicated in the 
survival and chemotherapy resistance of cancer cells.110 
Interestingly, the treatment of K562 with ZnO NPs 
decreased expression of genes that were previously charac-
terized as activators or downstream targets of NF-κB path-
way. These genes included KIT,111 CXCL1,112 VEGFA,113 
NUPR1,114 BCL2A,99 TNFAIP8,115 BIRC3116 and CFLAR 
(also known as FLICE-like IP).117 The activation of NF-κB 
pathway requires the phosphorylation of the inhibitors of 
NF-κB by I-kappa-B-kinase beta (IKBKB) leading to their 
degradation by proteasome and the translocation of NF-kB 
subunits to the nucleus in order to function as transcription 
factors.109 Interestingly, our transcriptomics data reported 
reduced expression of IKBKB, RELB, NFKB2 and REL in 
the treated cells, indicating that ZnO NPs targeted NF-κB 
pathway to promote apoptosis in K562 cells.
Conclusion
In summary, our study showed the capability of ZnO NPs 
to induce apoptosis in CML cells (K562), supporting ear-
lier studies that reported cytotoxicity of ZnO NPs on 
cancer cells. Using DNA microarray-based transcriptomic 
approach, we were able to identify alterations in the tran-
scriptome of K562 cells post treatment with ZnO NPs. Our 
transcriptomics findings were consistent with the apoptotic 
impact of ZnO NPs on K562 cells and revealed possible 
molecular mechanisms that were employed by the NPs to 
exert toxicity on the leukemic cells.
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